Li-Yao Zhu

Li-Yao Zhu

Auto-generated profile, based on publicly available information

Li-Yao Zhu

Department of Hepatology, the Fourth People's Hospital of Huai'an, Huai'an, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
PDF file
WDWei-Jing Dai
Wei-Jing Dai
LZLi-Yao Zhu
Li-Yao Zhu
ZYZhong-Yi Yan
Zhong-Yi Yan
YXYong Xu
Yong Xu
QWQilong Wang
Qilong Wang
XLXiao-Jie Lu
Xiao-Jie Lu
Owing to its easy-to-use and multiplexing nature, the genome editing tool CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats (CRISPR) associated nuclease 9) is revolutionizing many areas of medical research and one of the most amazing areas is its gene therapy potentials. Previous explorations into the therapeutic potentials of CRISPR-Cas9 were mainly conducted in vitro or in animal germlines, the translatability of which, however, is either limited (to tissues with adult stem cells amenable to culture and manipulation) or currently impermissible (due to ethic concerns). Recently, important progresses have been made on this regard. Several studies have demonstrated the ability of CRISPR-Cas9 for in vivo gene therapy in adult rodent models of human genetic diseases delivered by methods that are potentially translatable to human use. Although these recent advances represent a significant step forward to the eventual application of CRISPR-Cas9 to the clinic, there are still many hurdles to overcome, such as the off-target effects of CRISPR-Cas9, efficacy of homology-directed repair, fitness of edited cells, immunogenicity of therapeutic CRISPR-Cas9 components, as well as efficiency, specificity, and translatability of in vivo delivery methods. In this article, we introduce the mechanisms and merits of CRISPR-Cas9 in genome editing, briefly retrospect the applications of CRISPR-Cas9 in gene therapy explorations and highlight recent advances, later we discuss in detail the challenges lying ahead in the way of its translatability, propose possible solutions, and future research directions.

22 September 2020 in IEEE Sensors Journal
Verified
Journal Article
Closed access
Yudong ZhangYudong Zhang
Yudong Zhang
SSSuresh Satapathy
Suresh Satapathy
LZLi-Yao Zhu
Li-Yao Zhu
Juan M. Górriz SáezJuan M. Górriz Sáez
Juan M. Górriz Sáez
Shuihua WangShuihua Wang
Shuihua Wang
(Aim) COVID-19 pandemic causes numerous death tolls till now. Chest CT is an effective imaging sensor system to make accurate diagnosis. (Method) This paper proposed a novel seven layer convolutional neural network based smart diagnosis model for COVID-19 diagnosis (7L-CNN-CD). We proposed a 14-way data augmentation to enhance the training set, and introduced stochastic pooling to replace traditional pooling methods. (Results) The 10 runs of 10-fold cross validation experiment show that our 7L-CNN-CD approach achieves a sensitivity of 94.44±0.73, a specificity of 93.63±1.60, and an accuracy of 94.03±0.80. (Conclusion) Our proposed 7L-CNN-CD is effective in diagnosing COVID-19 in chest CT images. It gives better performance than several state-of-the-art algorithms. The data augmentation and stochastic pooling methods are proven to be effective.

13 June 2013 in Clinical and Translational Science
Verified
Journal Article
Closed access
PDF file
CXChunxiang Xia
Chunxiang Xia
WLWenwu Liu
Wenwu Liu
DZDongxiao Zeng
Dongxiao Zeng
LZLiyao Zhu
Liyao Zhu
XSXiaoli Sun
Xiaoli Sun
XSXuejun Sun
Xuejun Sun

1 August 2016 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
XZXiao-Yu Zhang
Xiao-Yu Zhang
LZLi-Yao Zhu
Li-Yao Zhu
YWYu-Gang Wang
Yu-Gang Wang
LWLi-Qing Wei
Li-Qing Wei
JZJian Zhou
Jian Zhou
WDWei-Jie Dai
Wei-Jie Dai
Purpose: To further observe and verify the effect of nonalcoholic fatty liver disease (NAFLD) on the response to antiviral therapy in patients with chronic hepatitis B (CHB) and investigate the relationship between the virologic response and insulin resistance. Patients and methods: A retrospective study was adopted and 61 NAFLD patients with HBeAg-positive CHB were included as the observation group (group A), and 64 patients with simple CHB were included as the control group (group B).
Results:
After 12 weeks of treatment with entecavir, the total virologic response rate in group A was statistically significantly lower than that in group B (P0.05). In weeks 48 and 96, there was no significant difference in the HBeAg seroconversion rates between the two groups (P>0.05). In weeks 12 and 24, there was also no significant difference in the alanine transaminase (ALT) normalization rate between the two groups (P>0.05). Then, in weeks 48 and 96, the ALT normalization rate of group A was obviously lower than that of group B (PM) according to the median value (M=2.79) of the baseline homeostatic model assessment method insulin resistance levels. In weeks 48 and 96, the ALT normalization rate of group A1 was significantly higher than that of group A2 (P<0.05). The correlation coefficient (r) of the baseline homeostatic model assessment method insulin resistance level and the severity of fatty liver in group A was 0.426 (P=0.001). Conclusion: NAFLD cannot affect the long-term total virologic response rate and HBeAg seroconversion rate in CHB patients treated with entecavir but can reduce the long-term biochemical response rate, which has a positive correlation with the severity of fatty liver and the insulin resistance index.

14 October 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
HHHaijin Huang
Haijin Huang
YBYan‐Zhi Bu
Yan‐Zhi Bu
XZXiao‐Yu Zhang
Xiao‐Yu Zhang
JLJuan Liu
Juan Liu
LZLi‐Yao Zhu
Li‐Yao Zhu
YFYong Fang
Yong Fang

26 July 2016 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
CYCheng-Bo Yu
Cheng-Bo Yu
LZLi-Yao Zhu
Li-Yao Zhu
YWYu-Gang Wang
Yu-Gang Wang
FLFen Li
Fen Li
XZXiaoyu Zhang
Xiaoyu Zhang
WDWei-Jie Dai
Wei-Jie Dai